CureMatch provides oncologists with clear, accessible, predictive treatment analysis to equip them with actionable knowledge tailored for each unique case.

CureMatch Treatment Options for Cancer

CureMatch is the trusted partner oncologists, cancer centers, NGS labs, concierge medicine providers — and their patients — rely upon, as PFS was significantly improved in 75% of patients treated with combination therapies based on high matching scores of targeted treatment option.*

Leverage our advanced proprietary algorithms and extensive curation of a deep swath of genomic, historical, and your personal data; resulting in customized ranking and scoring of genomically matched combination treatments for consideration.

Targeted Proteomics

Only by fully understanding the biology of a patient’s cancer can you determine the optimal treatment for that patient and, more to the point, their unique cancer. When an oncologist has access to proteomic and genomic data from FFPE tissue samples, they receive an additional and invaluable profile of the cancer at the molecular level.

*Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study- Sicklick…Kurzrock, Nature Medicine, 2019



It would take days to sort through the latest FDA-approved drugs and decide what combinations of drugs could provide the best outcomes based on a patient’s genomic results. CureMatch provides a clear report layout of ranked combination drug therapies targeting a patient’s cancer at the genomic level regardless of the diagnosed ‘type’ of cancer. This report is designed to provide actionable knowledge and insights oncologists or care teams need to make the best decisions for upcoming cancer drug treatments.

CureMatch Granted CPT Code 0794T

Oncologists will soon be able to submit claims to payers using a Category III CPT code, paving the way for wider adoption of precision treatment options.

The American Medical Association (AMA) has issued a new Current Procedural Terminology. CPT Code 0794T for the therapy matching and scoring service CureMatch offers. Patient-specific, assistive, rules-based algorithm for ranking pharmaco-oncologic treatment options. Based on the patient’s tumor-specific cancer marker information obtained from prior molecular pathology, immunohistochemical, or other pathology results which have been previously interpreted and reported separately. The AMA published this code on January 1, 2023, and it will be effective July 1, 2023, which will allow oncologists to track the use of CureMatch’s groundbreaking therapy matching system and submit for reimbursement.

CureMatch CPT Code 0794T on Nasdaq